

ORIGINAL PAPER

International society of blood transfusion working party on red cell immunogenetics and terminology: report of the Seoul and London meetings

J. R. Storry,^{1,*} L. Castilho,² Q. Chen,³ G. Daniels,⁴ G. Denomme,⁵ W. A. Flegel,⁶ C. Gassner,⁷ M. de Haas,⁸ C. Hyland,⁹ M. Keller,¹⁰ C. Lomas-Francis,¹¹ J. M. Moulds,¹² N. Noguez,¹³ M. L. Olsson,¹⁴ T. Peyrard,¹⁵ C. E. van der Schoot,¹⁶ Y. Tani,¹⁷ N. Thornton,¹⁸ F. Wagner,¹⁹ S. Wendel,²⁰ C. Westhoff¹¹ & V. Yahalom²¹

¹Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Lund, Sweden

²University of Campinas/Hemocentro, Campinas, Brazil

³Jiangsu Province Blood Center, Nanjing, China

⁴Bristol Institute for Transfusion Sciences, NHS Blood and Transplant, Bristol, UK

⁵Blood Center of Wisconsin, Milwaukee, WI, USA

⁶Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, USA

⁷Blutspende Zurich, Zurich, Switzerland

⁸Sanquin Blood Supply Foundation, Amsterdam, The Netherlands

⁹Australian Red Cross Blood Services, Brisbane, Qld, Australia

¹⁰American Red Cross Blood Services, Philadelphia, PA, USA

¹¹New York Blood Center, New York, NY, USA

¹²Grifols, San Marcos, TX, USA

¹³Banc de Sang i Teixits, Barcelona, Spain

¹⁴Department of Laboratory Medicine, Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden

¹⁵Institut National de la Transfusion Sanguine, Département Centre National de Référence pour les Groupes Sanguins, Inserm UMR_S1134, Paris, France

¹⁶Sanquin Research at CLB, Amsterdam, The Netherlands

¹⁷Osaka Red Cross Blood Center, Osaka, Japan

¹⁸International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK

¹⁹Red Cross Blood Service NSTOB, Springe, Germany

²⁰Blood Bank, Hospital Sirio-Libanes, São Paulo, Brazil

²¹NBGRM Magen David Adom, Ramat Gan, Israel

The Working Party has met twice since the last report: in Seoul, South Korea 2014, and in London, UK 2015, both in association with the International Society of Blood Transfusion (ISBT) Congress. As in previous meetings, matters pertaining to blood group antigen nomenclature were discussed. Eleven new blood group antigens were added to seven blood group systems. This brings the current total of blood group antigens recognized by the ISBT to 346, of which 308 are clustered within 36 blood groups systems. The remaining 38 antigens are currently unassigned to a known blood group system.

Key words: blood groups, genetics, terminology

The Working Party has met twice since the last report: in Seoul, South Korea 2014, and in London, UK 2015, both in association with the International Society of Blood

Transfusion (ISBT) Congress. As in previous meetings, matters pertaining to blood group antigen nomenclature were discussed.

A total of seven blood group antigens were added to four of the current blood group systems (Table 1). Three new blood group systems were created, one *de novo* (CD59), and two others Vel (VEL) and Augustine (AUG), elevating the previously homeless high-incidence antigens Vel and At^a, respectively. This brings the current total of

Correspondence: Jill Storry, Clinical Immunology & Transfusion Medicine, University and Regional Laboratories, Klinikgatan 21, SE-22185 Lund, Sweden.

E-mail: jill.storry@med.lu.se

Table 1 New antigens added to blood group systems

| Blood group system | Antigen number | Alt. name | Prevalence | Molecular basis | Protein change |
|--------------------|----------------|-----------------|-------------------|--|---|
| MNS | MNS47 | SARA | Low | <i>GYP A</i> c.240G>T | p.Arg80Ser |
| MNS | MNS48 | KIPP | Low | <i>GYP(B-A-B)</i> hybrid | p.Ser51 ^a GPB(1-26)-GPwB(27-54)- GPA(55-57)-Bs(58-103) |
| LU | LU23 | LUIT | High | <i>LU</i> c.469G>A, 1289C>T | p.Gly157Arg, p.Thr430Ile |
| LU | LU24 | LUGA | High | <i>LU</i> c.212G>A | p.Arg71His |
| DO | DO9 | DOLC | High | <i>ART4</i> c.566C>T | p.Thr189Met |
| DO | DO10 | DODE | High | <i>ART4</i> c.405C>A | p.Asp135Glu |
| GLOB | GLOB2 | PX2 | High ^b | <i>B3GALNT1</i> | ^c |
| Vel | VEL1 | Vel | High | <i>SMIM1</i> c.64_80delGTCAGCCTAGGGGCTGT | p.Ser22Glnfs*270 |
| CD59 | CD59.1 | – | High | <i>CD59</i> c.146delA | p.Asp49Valfs*31 |
| AUG | AUG1 | – | High | <i>ENT1</i> c.589 + 1G>C | p.Ser197fs |
| AUG | AUG2 | At ^a | High | <i>ENT1</i> c.1171G>A | p.Glu391Lys |

^aDistinguishes this protein from other known GP(B-A-B) hybrids.

^bAlthough PX2 is a product of β 1,3GalNAc-T1 and therefore present on RBCs of common phenotype, it is absent from RBCs of P₁^k and P₂^k phenotypes whilst highly expressed on RBCs of the p phenotype.

^cThus, all mutations causing the of P₁^k and P₂^k phenotypes also cause lack of PX2.

recognized blood group antigens to 346, of which 308 are clustered within 36 blood group systems.

Thus, there remain 38 serologically defined antigens that have not been assigned to a blood group system as yet. Six of those are in the high prevalence series (901), 17 in the low prevalence series (700) and a further 15 reside in one of six collections (the 200 series).

New blood group antigens

System 2: MNS

Two antigens have been added to the MNS system. Exome sequence analysis of samples from SARA+ and SARA– family members [1] identified a single nucleotide change c.240G>T in exon 3 of *GYP A*, which changes p.Arg80Ser. Sequence analysis of unrelated SARA+ samples confirmed the causative polymorphism [2]. The provisionally assigned number MNS47 was ratified by the working party and the low-prevalence series number 700052 has been made obsolete.

Molecular characterization of the GP.Kip and GP.Yak hybrid glycoporphins showed that they were one and the same and are encoded by the same *GYP(B-A-B)* hybrid that produces Mur, Hil, MUT, MINY, as well as the antigen KIPP [3, 4]. KIPP is recognized by the anti-Hop+Nob sera, Anek and Raddon, but not by antisera specific for the Hop or Nob antigens; as well as by the original anti-Kipp serum [5]. The resulting GP(B-A-B) hybrid retains p.Ser51, which distinguishes this hybrid protein from other known GP(B-A-B) hybrids, which have p.Tyr51. The provisionally assigned number MNS48 was ratified by the working party.

System 5: Lutheran

A new high-prevalence antigen, LUIT was assigned to the Lutheran blood group system based on the serology (LU23) and the identification of two changes in *LU*: sequencing showed two novel homozygous mutations, one in exon 4, c.469G>A (p.Gly157Arg), and one in exon 10, c.1289C>T (p.Thr430Ile). [6]. There was insufficient

Table 2 New blood group systems

| Blood group system | Symbol | Number | Reference sequence | Number of antigens | References |
|--------------------|--------|--------|--------------------|--------------------|---|
| Vel | VEL | 034 | NM_001163724 | 1 | Storry, Jöud <i>et al.</i> [11], Cvejic <i>et al.</i> [12], Ballif <i>et al.</i> [13] |
| CD59 | CD59 | 035 | NM_000611.5 | 1 | Anliker <i>et al.</i> [19], Hochsmann <i>et al.</i> [20] |
| Augustine | AUG | 036 | NM_001078175.2 | 2 | Daniels <i>et al.</i> [21] |

evidence to determine which of the amino acids are responsible for the absence of the antigen, and thus, the allele number remains provisional: *LU*02.-23*. The proband's RBCs typed Lu:–1,2,3,4,5,6w,8,13, although the weakening of LU6 expression is not understood.

A second new high-prevalence antigen named LUGA (LU24) was assigned to Lutheran based on the serology and the identification of a single missense change c.212G>A (p.Arg71His) in exon 3 of *LU* [7]. The proband's plasma failed to react with Lu:–12 and Lu:–17 RBCs, as well as Lu(a–b–) RBCs and her own cells. However, anti-Lu12 could be excluded since the RBCs of the proband were reactive with anti-Lu12, and anti-Lu17 could be excluded based on the sequencing results which predicted homozygosity for Lu17. The serology may also be explained in part by the location of the novel amino acid change, which is predicted to lie in the first extracellular immunoglobulin domain of the Lu glycoprotein that also expresses Lu12, LURC, Lu^a/Lu^b, Lu21, Lu5 and Lu17. In addition, homozygosity for two silent changes were observed in exon 6 (c.711C>T and c.714C>T).

System 14: Dombrock

Two new high-prevalence antigens were assigned to the Dombrock blood group system, based both on serology and molecular analysis. The first, named DOLC, was based on the serology (D09) and the identification of the c.566C>T (p.Thr189Met) change in exon 2 of *DO*. The proposita's RBCs typed Do(a+b–), Hy+, Jo(a+), DOYA+, DOLG+ and her plasma was non-reactive with Gy(a–) RBCs and only weakly reactive with Hy– RBCs [8].

Similarly, an antibody with serological characteristics consistent with Dombrock antibodies, in that it was non-reactive with trypsin-treated RBCs and weakly reactive only with DTT-treated RBCs, was shown to be directed at a new high-prevalence antigen, subsequently named DODE. Molecular analysis identified a c.405C>A (p.Asp135Glu) change in exon 2 of *DO* [9]. The antigen was assigned as D010.

System 28: GLOB

PX2, a carbohydrate antigen belonging to the GLOB collection (209) and determined by a terminal β 3-*N*-acetyl-galactosamine added to paragloboside, was shown to be the product of *B3GALNT1*, also known as the P antigen synthase [10]. PX2 was therefore reclassified as a member of the GLOB blood group system (028). The P antigen was previously assigned the name GLOB1 (028001), and thus, PX2 was named GLOB2 (028002). This leaves LKE as the sole remaining antigen in the GLOB (209) collection, and the former PX2 number, 209004, was made obsolete.

New blood group systems

System 34: VEL

A founder mutation in the previously undescribed small integral protein 1 (*SMIM1*) gene, c.64_80delGTCAGCC-TAGGGGCTGT, was identified as the primary molecular basis underlying the Vel– phenotype [11–13]. The presence or absence of Vel antigen was directly correlated to the presence or absence of SMIM1, a single-pass integral membrane protein. The considerable variation in antigen strength was shown not only to correlate with zygosity for the wild-type *SMIM1* but could also be affected by two rare missense mutations, c.152T>A and c.152T>G (encoding p.Met51Lys and p.Met51Arg, respectively). Furthermore, a single nucleotide polymorphism in intron 2 (rs1175550) situated in a GATA-1 binding site also considerably influenced Vel antigen expression [12, 14, 15].

Based on the molecular and biochemical evidence, Vel was assigned blood group system status (034); system name: Vel; symbol: VEL, antigen: VEL1 (034001). There was no molecular evidence that ABTI was dependent on SMIM1 for expression, despite historical serological evidence of a phenotypic association [16]. As a consequence, collection 200212 was made obsolete and ABTI was returned to the 901 series and reassigned its old number (901015).

As yet, the function of SMIM1 remains unknown; however, elegant work by Arnaud and colleagues has suggested the protein to be a type 2 integral membrane protein [17].

System 35: CD59

Based on the publication of a case report in which a young patient with a CD59 deficiency produced an alloantibody specific for CD59, blood group status was unanimously assigned [18–20]. Both the blood group system and symbol are CD59 (035), and the antigen defined by the antibody maker in this case report has been named CD59.1.

System 36: AUG

The erythrocyte protein, equilibrative nucleoside transporter 1 (*ENT1*), was identified as the carrier of the At^a antigen. Daniels and colleagues showed that the At(a–) phenotype in individuals of African origin is defined by an amino acid polymorphism on the ENT1 protein (c.1171G>A; p.Glu391Lys) and that the At(a–) members of a family affected by bone malformation lacked the protein due to an inactivating mutation in the *ENT1* gene: c.589+1G>C [21]. Based on the evidence, and

following a discussion on names, the blood group system Augustine (symbol AUG) was created (036). The antigen defined by the antibody produced by the null phenotype was named AUG1, and the antigen defined by the amino acid Glu391 (At^a) was named AUG2.

Gene terminology

The Working Party continues to update the allele nomenclature tables and these can be found on the ISBT website. (<http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology/>) We anticipate an expansion of these tables, and a more detailed monograph on guidelines and usage is planned.

Acknowledgements

Since the last report [22], Dr Philippe Rouger and Dr Lung-Chi Yu resigned from the Working Party. We sincerely thank them for their helpful contributions during the years. We also note with sadness the passing of our dear colleague Professor George Garratty, who was an active member of the Working Party to the end. As members of the Working Party, all authors have contributed equally to the discussion and conclusions drawn in this paper. CAH is funded by the Australian Red Cross Blood Service and acknowledges the Australian Governments that fund the Blood Service for provision of blood, blood products and services to the Australian Community.

Conflict of interests

The authors declare no conflict of interest.

References

- 1 Stern DA, Hawksworth DN, Watt JM, *et al.*: A new low-frequency red cell antigen, 'SARAH'. *Vox Sang* 1994; **67**:64–67
- 2 McBean RS, Hyland CA, Hendry JL, *et al.*: SARA: a "new" low-frequency MNS antigen (MNS47) provides further evidence of the extreme diversity of the MNS blood group system. *Transfusion* 2015; **55**:1451–1456
- 3 Uchikawa M, Ogasawara K, Suzuki Y, *et al.*: A new GP(B-A-B) hybrid molecule (GP.YAK) with Miltenberger phenotype. *Vox Sang* 2012; **103**:214
- 4 Lopez GH, Wei L, Ji Y, *et al.*: GYP*Kip, a novel GYP(B-A-B) hybrid allele, encoding the MNS48 (KIPP) antigen. *Transfusion* 2016; **56**:539–541
- 5 Green C, Poole J, Ford D, *et al.*: A postulated glycoporphin B-A-B hybrid demonstrating heterogeneity of anti-Hop and anti-Nob sera. *Transfu Med* 1992; **2**:67
- 6 Hustinx H, Lejon-Crottet S, Henny C, *et al.*: LUIT: a novel high incidence antigen in the Lutheran blood group system. *Vox Sang* 2014; **107**:172
- 7 Brennan S, Shakarian G, Vege S, *et al.*: A new antibody in the Lutheran blood group system against a novel high-prevalence antigen named LUGA. *Transfusion* 2015; **55**:36A
- 8 Karamatic Crew V, Thornton N, Bullock T, *et al.*: Serological and molecular characterisation of DOLC, a novel high incidence antigen in the Dombrock blood group system. *Vox Sang* 2013; **105**:30
- 9 Shakarian G, Vege S, Hue-Roye K, *et al.*: A Dombrock system antibody detects a new high-prevalence antigen, DODE. *Transfusion* 2015; **55**:35A–36A
- 10 Westman JS, Benktander J, Storry JR, *et al.*: Identification of the molecular and genetic basis of PX2, a glycosphingolipid blood group antigen lacking on globoside-deficient erythrocytes. *J Biol Chem* 2015; **290**:18505–18518
- 11 Storry JR, Joud M, Christophersen MK, *et al.*: Homozygosity for a null allele of SMIM1 defines the Vel-negative blood group phenotype. *Nat Genet* 2013; **45**:537–541
- 12 Cvejic A, Haer-Wigman L, Stephens JC, *et al.*: SMIM1 underlies the Vel blood group and influences red blood cell traits. *Nat Genet* 2013; **45**:542–545
- 13 Ballif BA, Helias V, Peyrard T, *et al.*: Disruption of SMIM1 causes the Vel- blood type. *EMBO Mol Med* 2013; **5**:751–761
- 14 Haer-Wigman L, Stegmann TC, Solati S, *et al.*: Impact of genetic variation in the SMIM1 gene on Vel expression levels. *Transfusion* 2015; **55**:1457–1466
- 15 Christophersen MK, Jöud M, Thuresson B, *et al.*: Genetic variants regulate expression of SMIM1 and the Vel blood group antigen. *Vox Sang* 2014; **107**:16
- 16 Banks J, Poole J, Das Gupta C, *et al.*: Two new cases of anti-ABTI showing an association between ABTI and Vel. *Vox Sang* 2004; **87**:38
- 17 Arnaud L, Kelley LP, Helias V, *et al.*: SMIM1 is a type II transmembrane phosphoprotein and displays the Vel blood group antigen at its carboxyl-terminus. *FEBS Lett* 2015; **589**:3624–3630
- 18 Weinstock C, Von Zabern I, Höchsmann B, *et al.*: CD59 defines a new blood group system. *Vox Sang* 2013; **105**:29–30
- 19 Anliker M, von Zabern I, Hochsmann B, *et al.*: A new blood group antigen is defined by anti-CD59, detected in a CD59-deficient patient. *Transfusion* 2014; **54**:1817–1822
- 20 Hochsmann B, Dohna-Schwake C, Kyrieleis HA, *et al.*: Targeted therapy with eculizumab for inherited CD59 deficiency. *N Engl J Med* 2014; **370**:90–92
- 21 Daniels G, Ballif BA, Helias V, *et al.*: Lack of the nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization. *Blood* 2015; **125**:3651–3654
- 22 Storry JR, Castilho L, Daniels G, *et al.*: International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Cancun report (2012). *Vox Sang* 2014; **107**:90–96

Appendix 1. Members of the Working Party for Red Cell Immunogenetics and Blood Group Terminology 2014–2016

Dr Jill R Story (Chair): Dept. of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Lund, Sweden. jill.storry@med.lu.se

Prof Dr Lilian Castilho: University of Campinas/Hemocentro, Campinas, Brazil. castilho@unicamp.br

Dr Qing Chen: Jiangsu Province Blood Center, Nanjing, Jiangsu, China. qngchen@gmail.com

Dr Geoff L Daniels: International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK. geoff.daniels.bris@outlook.com

Prof Dr Masja de Haas: Sanquin Blood Supply Foundation, Amsterdam, The Netherlands. m.dehaas@sanquin.nl

Dr Greg Denomme: Blood Center of Wisconsin, Milwaukee, WI, USA. greg.denomme@bcw.edu

Prof Dr Bill (W)A Flegel: Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA. flegelwa@cc.nih.gov

Dr Christoph Gassner: Blutspende Zurich, Zurich, Switzerland. c.gassner@zhbsd.ch

Dr Catherine Hyland: Australian Red Cross Blood Services, Brisbane, Australia. chyland@arcbs.redcross.org.au

Dr Margaret Keller: American Red Cross Blood Services, Philadelphia, PA, USA. Margaret.Keller@redcross.org

Ms Christine Lomas Francis: New York Blood Center, New York, NY, USA. cfrancis@nybloodcenter.org

Dr Joann M Moulds: GRIFOLS ImmunoHematology Center, 201 Carlson Circle, San Marcos, TX, USA. joann.moulds@grifols.com

Dr Nuria Nogues: Banc de Sang i Teixits, Barcelona, Spain. nnogues@bst.cat

Prof Dr Martin L Olsson: Department of Laboratory Medicine, Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden. Martin_L.Olsson@med.lu.se

Dr. Thierry Peyrard, Institut National de la Transfusion Sanguine, Département Centre National de Référence pour les Groupes Sanguins, Paris, France. tpeyrard@ints.fr

Prof Dr C Ellen van der Schoot: Sanquin Research at CLB, Amsterdam, The Netherlands. e.vanderschoot@sanquin.nl

Dr Yoshihiko Tani: Japanese Red Cross Kinki Block Blood Center, Ibaraki-shi Osaka, Japan. y-tani@kk.bbc.jrc.or.jp

Ms Nicole Thornton: International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK. nicole.thornton@nhsbt.nhs.uk

Dr Franz Wagner, Red Cross Blood Service NSTOB, Springe, Germany. fwagner@bsd-nstob.de

Dr Silvano Wendel: Blood Bank, Hospital Sirio-Libanes, São Paulo, Brazil. snwendel@terra.com.br

Dr Connie M Westhoff: New York Blood Center, New York, NY, USA. cwesthoff@nybloodcenter.org

Dr Vered Yahalom: NBGRL Magen David Adom, Ramat Gan, Israel. veredy@mda.org.il